News|Articles|October 2, 2023
New Market Opportunities for Pathogen-Targeted mAbs
Author(s)AGC Biologics
This research outlines recent changes in the monoclonal antibody market, the great potential for pathogen-focused mAb treatments and important industry factors impacting how to antibody products can navigate through clinical stages.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Novartis Calls for Global Governments to Address Global Trade Policy
2
How FDA’s Bayesian Guidance Could Accelerate Adaptive Trial Design in Biopharmaceuticals
3
Agenus Closes $141 Million Immunotherapy Collaboration with Zydus Lifesciences
4
Beyond Transactional: Collaborative Partnerships for Rapid, Flexible Biologics Development
5